Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
- PMID: 14973191
- PMCID: PMC365734
- DOI: 10.1073/pnas.0307323101
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Abstract
A large number of tiny noncoding RNAs have been cloned and named microRNAs (miRs). Recently, we have reported that miR-15a and miR-16a, located at 13q14, are frequently deleted and/or down-regulated in patients with B cell chronic lymphocytic leukemia, a disorder characterized by increased survival. To further investigate the possible involvement of miRs in human cancers on a genome-wide basis, we have mapped 186 miRs and compared their location to the location of previous reported nonrandom genetic alterations. Here, we show that miR genes are frequently located at fragile sites, as well as in minimal regions of loss of heterozygosity, minimal regions of amplification (minimal amplicons), or common breakpoint regions. Overall, 98 of 186 (52.5%) of miR genes are in cancer-associated genomic regions or in fragile sites. Moreover, by Northern blotting, we have shown that several miRs located in deleted regions have low levels of expression in cancer samples. These data provide a catalog of miR genes that may have roles in cancer and argue that the full complement of miRs in a genome may be extensively involved in cancers.
Figures




Similar articles
-
Characterization of FRA7B, a human common fragile site mapped at the 7p chromosome terminal region.Cancer Genet Cytogenet. 2010 Oct 1;202(1):47-52. doi: 10.1016/j.cancergencyto.2010.06.008. Cancer Genet Cytogenet. 2010. PMID: 20804921
-
Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers.FEBS Lett. 1998 Oct 9;436(3):403-10. doi: 10.1016/s0014-5793(98)01134-x. FEBS Lett. 1998. PMID: 9801158
-
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9. doi: 10.1073/pnas.242606799. Epub 2002 Nov 14. Proc Natl Acad Sci U S A. 2002. PMID: 12434020 Free PMC article.
-
Transcribed ultraconserved region in human cancers.RNA Biol. 2013 Dec;10(12):1771-7. doi: 10.4161/rna.26995. Epub 2013 Nov 4. RNA Biol. 2013. PMID: 24384562 Free PMC article. Review.
-
Are fragile sites "hot-spots": a causative factor in tumor biology.J Exp Ther Oncol. 2012;10(1):19-29. J Exp Ther Oncol. 2012. PMID: 22946341 Review.
Cited by
-
MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2.Mol Cancer. 2024 Oct 21;23(1):235. doi: 10.1186/s12943-024-02094-9. Mol Cancer. 2024. PMID: 39434078 Free PMC article.
-
Role of microRNAs in Predicting the Prognosis of Cervical Cancer Cases: A Systematic Review and Meta-Analysis.Asian Pac J Cancer Prev. 2021 Apr 1;22(4):999-1006. doi: 10.31557/APJCP.2021.22.4.999. Asian Pac J Cancer Prev. 2021. PMID: 33906290 Free PMC article.
-
A novel onco-miR-365 induces cutaneous squamous cell carcinoma.Carcinogenesis. 2013 Jul;34(7):1653-9. doi: 10.1093/carcin/bgt097. Epub 2013 Mar 20. Carcinogenesis. 2013. PMID: 23514750 Free PMC article.
-
MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma.Oncotarget. 2015 Feb 10;6(4):2421-33. doi: 10.18632/oncotarget.2965. Oncotarget. 2015. PMID: 25537516 Free PMC article.
-
Molecular pathways: microRNAs as cancer therapeutics.Clin Cancer Res. 2012 Aug 15;18(16):4234-9. doi: 10.1158/1078-0432.CCR-11-2010. Epub 2012 Jun 18. Clin Cancer Res. 2012. PMID: 22711704 Free PMC article. Review.
References
-
- Ke, X.-S., Liu, C.-M., Liu, D.-P. & Liang, C.-C. (2003) Curr. Opin. Chem. Biol. 7, 516-523. - PubMed
-
- Moss, E. G. (2003) MicroRNAs in Noncoding RNAs: Molecular Biology and Molecular Medicine (Eurekah.com), pp. 98-114.
-
- Pasquinelli, A. E., Reinhart, B. J., Slack F., Martindale, M. Q., Kuroda, M. I., Maller, B., Hayward, D. C., Ball, E. E., Degnan, B., Muller, P., et al. (2000) Nature 408, 86-89. - PubMed
-
- Ambros, V. (2003) Cell 113, 673-676. - PubMed
-
- Xu, P., Vernooy, S. Y., Guo, M. & Hay, B. A. (2003) Curr. Biol. 13, 790-795. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical